First Author | Jadad score | Inclusion/exclusion criteria specified | Randomization process described | Use of any blinding | Placebo-controlled | Reported loss to follow-up | Intention-to treat analysis | Potential important baseline differences | Power calculation |
---|---|---|---|---|---|---|---|---|---|
Allaqaband 25 | 3 | yes/no | yes | yes | yes | no | no | no | yes |
Baker 26 | 2 | yes/yes | yes | no | yes | no | yes | no | yes |
Briguori 27 | 1 | yes/no | yes | no | no | no | unclear | yes | no |
Diaz-Sandoval 28 | 4 | yes/yes | yes | yes | no | yes | unclear | yes | no |
Durham 29 | 5 | yes/yes | yes | yes | yes | yes | unclear | no | yes |
Efrati 30 | 4 | yes/yes | no | yes | yes | yes | unclear | no | no |
Fung 31 | 4 | yes/yes | yes | no | no | no | yes | no | yes |
Goldenberg 32 | 5 | yes/yes | yes | yes | yes | no | unclear | no | yes |
Kay 33 | 5 | yes/yes | yes | yes | yes | yes | yes | no | yes |
Kefer 34 | 4 | yes/yes | yes | yes | yes | yes | unclear | yes | no |
MacNeill 35 | 4 | yes/yes | yes | no | yes | no | unclear | no | yes |
Oldemeyer 36 | 4 | yes/yes | yes | yes | no | yes | unclear | no | no |
Shyu 37 | 3 | yes/yes | yes | yes | no | yes | unclear | no | no |
Vallero 38 | 2 | yes/yes | yes | no | no | no | unclear | yes | no |